Core Viewpoint - The stock of Heptagon Pharmaceuticals-B (02142) rose over 6% following the announcement of a non-exclusive licensing agreement between its subsidiary, Nona Bio, and Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Company Developments - Heptagon Pharmaceuticals-B's stock increased by 6.16%, reaching HKD 14.68, with a trading volume of HKD 8.0214 million [1] - Nona Bio, a wholly-owned subsidiary of Heptagon Pharmaceuticals-B, has entered into a non-exclusive licensing agreement with Pfizer [1] - The agreement allows Pfizer to utilize Nona Bio's proprietary HCAb platform globally for the development of fully human only heavy chain antibodies [1] Group 2: Financial Implications - Nona Bio will receive an upfront payment from Pfizer and is entitled to receive regulatory, clinical, and commercial milestone payments [1] - The collaboration will leverage Nona Bio's HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]
港股异动 | 和铂医药-B(02142)早盘涨超6% 子公司诺纳生物与辉瑞订立非独家授权协议